CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Sodium Bicarbonate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current, To Be Discontinued. First FDA posting: 2017-03-01. Latest FDA row update: 2026-10-01.
FDA lists 15 package records, with companies: Amphastar Pharmaceuticals, Inc., Exela Pharma Sciences, LLC, Fresenius Kabi USA, LLC, Hospira, Inc., Hospira, Inc., a Pfizer Company, International Medication Systems, Limited, Long Grove Pharmaceuticals LLC, Long Grove Pharmaceuticals, LLC. Package NDCs: 0409-4900-14, 0409-4916-14, 0409-5534-14, 0409-5555-01, 0409-5555-02, 0409-6625-14, 0409-6625-35, 0409-6637-14, 51754-5001-5, 51754-5011-4, 51754-5012-4, 63323-083-05, 63323-089-50, 76329-3352-1, 81298-7620-3.
FDA shortage reason: Demand increase for the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | 76329-3352-1 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1) | Limited Availability | 2026-09-16 |
| Exela Pharma Sciences, LLC | 51754-5012-4 | Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4) | Available | 2026-10-01 |
| Exela Pharma Sciences, LLC | 51754-5001-5 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5) | Available | 2026-10-01 |
| Exela Pharma Sciences, LLC | 51754-5011-4 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4) | Available | 2026-10-01 |
| Fresenius Kabi USA, LLC | 63323-083-05 | Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-089-50 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50) | Available | 2026-09-15 |
| Hospira, Inc., a Pfizer Company | 0409-5555-01 | Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01) | Limited Availability | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-5555-02 | Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02) | Limited Availability | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-5534-14 | Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14) | Not stated | 2025-11-07 |
| Hospira, Inc., a Pfizer Company | 0409-6625-14 | Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-6625-35 | Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-4916-14 | Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14) | Not stated | 2025-11-07 |
| Hospira, Inc., a Pfizer Company | 0409-4900-14 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14) | Not stated | 2025-11-07 |
| Hospira, Inc., a Pfizer Company | 0409-6637-14 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14) | Not stated | 2025-11-07 |
| Long Grove Pharmaceuticals LLC | 81298-7620-3 | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3) | Available | 2026-10-01 |
Source facts
Grouped generic ingredient: Sodium Bicarbonate Injection · 15 package records
Therapeutic categories: Endocrinology/Metabolism, Gastroenterology, Pediatric
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.